PLANREFERENCE OUTLINE

Risk Management Plan (RMP)

Risk management plan built around the safety specification: important identified risks, important potential risks and missing information, each carrying the pharmacovigilance activity that investigates it, the minimisation measure that contains it, and a pre-specified effectiveness indicator. Maps to EU GVP Module V and ICH E2E.

What a template is not

A template is a document baseline to adapt inside your own quality system. SPEQ does not approve, validate, or take responsibility for what you issue from it, and using one is not evidence of compliance.

CHECKING ACCESS

Checking your Professional access…

REGULATIONS MAPPED
EU GVP ModulesICH E2E
DOCUMENT TYPE
Plan
LAST UPDATED
August 2026
PURPOSE

A risk management plan describes a product’s safety profile, what remains uncertain about it, and the activities that will characterise and minimise its risks. Its centre of gravity is the safety specification — the honest statement of important identified risks, important potential risks and missing information. A thin specification produces downstream activities that measure nothing in particular, and that is where the plan usually fails.

What's Inside

Product and plan identification stating why this version exists and what actually triggered it
Safety specification separating important identified risks, important potential risks and missing information
Pharmacovigilance plan mapped concern by concern, distinguishing routine activity from additional activity
Each additional activity carrying its objective, so completion can be judged rather than simply declared
Risk minimisation measures with the behaviour change each one is intended to produce
Pre-specified effectiveness indicators, chosen before deployment and separating process measures from outcome measures
Version history and approval by author, QPPV and regulatory affairs, with the changes summarised

How to Use It

1Build the safety specification before anything downstream; a thin specification produces activities that measure nothing in particular.
2Justify each omission as well as each entry — a population excluded from the trial programme is missing information unless you can say why not.
3State the objective of each additional activity, not only its design; an activity with no stated objective cannot be judged complete.
4Say what behaviour each minimisation measure is meant to change, because that is what the indicator has to detect.
5Choose effectiveness indicators before the measure is deployed; one chosen afterwards tends to be the one the data supports.
6Update the plan when the safety profile moves, not only at the next scheduled submission, and summarise what changed.
DOCUMENT CONTENTS

The full section structure of this template — every section and sub-section, so you can use it as a baseline for your own site document.

Document Control
Document InformationApproval SignaturesRevision HistoryDistribution List
1Product and Plan Identification
2Safety Specification
Important identified risksImportant potential risksMissing information
3Pharmacovigilance Plan
4Risk Minimisation Measures
5Measuring Effectiveness
6Summary of Changes and Approval
REGULATORY CONTEXT

EU GVP Module V sets the risk-management-system requirements for products authorised in the EU, and ICH E2E establishes the safety-specification and pharmacovigilance-planning structure the plan follows. Neither decides what counts as an important potential risk for your product, which populations are genuinely missing information, or when a minimisation measure has worked — those judgements are the marketing authorisation holder’s and are assessed on the reasoning recorded here. The document structure and guidance notes are SPEQ’s practitioner synthesis, not regulator text.

MAPPED STANDARDS
EU GVP ModulesICH E2E
Browse the standards catalog →